Enfusion Operating Margin from 2010 to 2024

ENFN Stock  USD 9.94  0.08  0.80%   
Enfusion Operating Profit Margin yearly trend continues to be very stable with very little volatility. Operating Profit Margin is likely to grow to 0.07 this year.
Check Enfusion financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Enfusion's main balance sheet or income statement drivers, such as Tax Provision of 867 K, Net Interest Income of 1.7 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 4.66, Dividend Yield of 0.0034 or PTB Ratio of 16.74. Enfusion financial statements analysis is a perfect complement when working with Enfusion Valuation or Volatility modules.
  
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Latest Enfusion's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Enfusion over the last few years. It is Enfusion's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Enfusion's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.06 %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Enfusion Operating Margin Regression Statistics

Arithmetic Mean0
Geometric Mean0.20
Coefficient Of Variation61,435
Mean Deviation0.34
Median0.23
Standard Deviation0.69
Sample Variance0.48
Range2.7048
R-Value(0.35)
Mean Square Error0.45
R-Squared0.12
Significance0.20
Slope(0.05)
Total Sum of Squares6.67

Enfusion Operating Margin History

2024 0.0719
2023 0.0685
2022 -0.0796
2021 -2.47
2020 0.0763

About Enfusion Financial Statements

Enfusion investors utilize fundamental indicators, such as Operating Margin, to predict how Enfusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois. Enfusion Inc operates under SoftwareApplication classification in the United States and is traded on New York Stock Exchange. It employs 892 people.

Pair Trading with Enfusion

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.

Moving together with Enfusion Stock

  0.67U Unity Software Aggressive PushPairCorr
  0.72DJCO Daily Journal CorpPairCorr
  0.77AI C3 Ai Inc Earnings Call This WeekPairCorr
  0.81BL BlacklinePairCorr
  0.62DT Dynatrace Holdings LLCPairCorr

Moving against Enfusion Stock

  0.7VERB VERB TECHNOLOGY PANY Tech BoostPairCorr
  0.35VTEX VTEXPairCorr
  0.33EGAN eGainPairCorr
The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:
Check out the analysis of Enfusion Correlation against competitors.
To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Application Software space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.04
Revenue Per Share
2.155
Quarterly Revenue Growth
0.154
Return On Assets
0.0592
The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.